Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery

Plain-language summary

This study examined the effect of Etoricoxib and Dexamethasone given before surgery on wound healing and clinical signs in people undergoing impacted third molar (wisdom tooth) surgery. It enrolled systemically healthy people aged 18-30. It was conducted in Phase 4 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Completed

Sponsor

University of Belgrade

Intervention

Etoricoxib 90 Mg Oral Tablet, Dexamethasone 4mg

Start date

10/11/2021

Estimated completion

12/26/2022

Countries

Serbia

Related genes

Locations

• Belgrade, Serbia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Systemically healthy individuals (ASA I by American Society of Anesthesiologists classification);
* Age 18-30 years;
* Absence of hypersensitivity to any of the medications in the study;
* Subjects capable to understand the protocol and sign an informed consent form.

Exclusion Criteria:

* Systemic disorders;
* Individuals in gestation or lactation period;
* Radiographic presence of potential cystic or tumorous lesions in the region of the extraction-required IMTM;
* Any symptoms or clinical signs of the infection caused by the extraction-required IMTM up to 10 days preoperatively;
* Use of NSAIDs or corticosteroids within 10 days before the surgery.